Batu Biologics, an immuno-oncology company based out of San Diego dedicated to the development of its polyvalent tumor endothelium vaccine, ValloVax, announced today the appointment of Santosh Kesari, MD, PhD, FANA to its scientific advisory board. Batu Biologics has recently filed an Investigational New Drug (IND) application with the FDA seeking to initiate a Phase I dose-escalation study for ValloVax in patients with non-small cell lung cancer.